Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics

Citation

As Published
http://dx.doi.org/10.1073/pnas.1314651111

Publisher
National Academy of Sciences (U.S.)

Version
Final published version

Accessed
Thu Jan 24 09:21:39 EST 2019

Citable Link
http://hdl.handle.net/1721.1/91284

Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.

Detailed Terms
The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
With noncommunicable diseases (NCDs) now constituting the majority of global mortality, there is a growing need for low-cost, noninvasive methods to diagnose and treat this class of diseases, especially in resource-limited settings. Molecular biomarkers combined with low-cost point-of-care assays constitute a potential solution for diagnosing NCDs, but the dearth of naturally occurring, predictive markers limits this approach. Here, we describe the design of exogenous agents that serve as synthetic biomarkers for NCDs by producing urinary signals that can be quantified by a companion paper test. These synthetic biomarkers are composed of nanoparticles conjugated to ligand-encoded reporters via protease-sensitive peptide substrates. Upon delivery, the nanoparticles passively target diseased sites, such as solid tumors or blood clots, where up-regulated proteases cleave the peptide substrates and release reporters that are cleared into urine. The reporters are engineered for detection by sandwich immunoassays, and we demonstrate their quantification directly from unmodified urine; furthermore, capture antibody specificity allows the probes to be tailored for multiple diseases, form a generalized diagnostic platform for NCDs that can be applied in almost any setting without expensive equipment or trained medical personnel. Together, the LFA and injectable synthetic biomarkers, which could be tailored for multiple diseases, form a generalized diagnostic platform for NCDs that can be applied in almost any setting without expensive equipment or trained medical personnel.

In the last several decades, global health challenges have dramatically shifted, with substantial reductions in the burden of infectious diseases (e.g., HIV, tuberculosis, and malaria) and simultaneous growth in the prevalence of noncommunicable diseases (NCDs) such as stroke, heart disease, and cancer, which constitute an increasing majority of global mortality (1, 2). Strikingly, NCDs disproportionately affect the developing world: low- and middle-income countries bear nearly 80% of the world’s NCD burden (3), and cardiovascular diseases and cancer have been the first and second, respectively, highest causes of mortality in the developing world since 2001 (4). Diagnosing NCDs in remote and/or poor settings is difficult without access to costly imaging modalities [e.g., computed tomography (CT)/MRI], well-equipped clinical laboratories [e.g., for histopathology], and trained medical personnel. Consequently, developing diagnostics for NCDs that are cost effective and can be easily implemented remains an important goal in global health. One promising approach is to detect disease biomarkers from readily accessible bodily fluids with point-of-care (POC) devices that are inexpensive, noninvasive, and do not require trained medical personnel. Despite widespread interest, the lack of predictive, validated biomarkers significantly limits the types of NCDs that can be detected at the POC (5–7).

Rather than searching for endogenous biomarkers, a promising strategy is to engineer exogenous agents that can specifically probe for the presence of diseased tissue. Radiolabeled glucose is an example of a common exogenous agent used with PET to reveal the location of metabolically active tumors. Inspired by engineered approaches, our group recently outlined a framework whereby protease-sensitive nanoparticles (NPs) called “synthetic biomarkers” are administered to detect NCDs including liver fibrosis, cancer, and thrombosis noninvasively (8, 9). These peptide-coated NPs probe diseased sites and, in response to cleavage by local dysregulated proteases, release mass-encoded reporters that then filter into the urine for analysis by mass spectrometry. In practice, administering NPs and collecting urine samples are both well-suited for the POC, but the need for a mass spectrometer to analyze the urinary cleavage fragments limits the utility of mass-encoded synthetic biomarkers for global health applications.

To address these difficulties, we reformulated our synthetic biomarkers to release ligand-encoded reporters designed for detection by a companion POC diagnostic comprised of paper test strips, a well-established technology used to screen and monitor diseases with readily available biomarkers (10, 11). The
The benefits of paper testing include low cost, rapid diagnosis, and no need for complex equipment or technical expertise (11, 12). Paper tests operate by wicking a biological specimen (commonly urine, saliva, or blood) containing a target analyte to regions where subsequent chemical or antibody-mediated analyses are detected by direct observation (13) or inexpensive and accessible quantitative imaging (14–16). Recently, paper diagnostics have been developed for quantitative assays like monitoring transaminases released by liver damage (13) or detecting infectious diseases like HIV-1, malaria, or trichinellosis (17). Unfortunately, the scarcity of naturally occurring biomarkers has limited use of paper diagnostics for NCDs. Consequently, combining paper diagnostics with synthetic biomarkers that sensitively and specifically indicate disease from the urine may provide a simple and low-cost method to diagnose NCDs in resource-limited settings.

To pursue the goal of developing affordable POC tests for NCDs, we engineer synthetic biomarkers to detect thrombosis and colorectal cancer (CRC) from the urine by custom lateral flow assay (LFA), a variant of paper tests. Thrombosis, the formation of obstructive blood clots, occurs in many cardiovascular-associated disorders (e.g., stroke and heart attack) and is characterized by the activation of the plasma protease thrombin that mediates fibrin clot formation. In CRC and most solid cancers, tumors produce matrix metalloproteinases (MMPs) to facilitate growth, angiogenesis, and metastatic spread (18). To detect these diseases, we develop thrombin- and MMP-sensitive NPs by conjugating substrate–reporter tandem peptides to the surface of NPs (Fig. 1A). When administered, these NPs probe diseased tissues (blood clots or tumors) where local up-regulated proteases (thrombin or MMPs, respectively) cleave their surface coat of peptides, releasing reporters that are concentrated into the urine. The urinary reporters are functionalized with structurally distinct ligands for capture onto paper test strips adsorbed with ligand-binding antibodies (Fig. 1B). Beyond thrombosis and CRC, this approach may be amenable to many noncommunicable and infectious diseases in which aberrant protease activities are implicated.

**Fig. 1.** Protease-sensitive NPs for POC urinary monitoring of disease. (A) Synthetic biomarkers were synthesized by conjugating substrate–reporter tandem peptides to carrier iron oxide NPs. Proteolytic cleavage of the linking peptide substrate liberates ligand-encoded reporters that filter into urine. (B) (I) A patient suspected of harboring a disease receives a disease-tuned diagnostic nanoworm (NW) mixture. (II) NWs infiltrate the disease site and release reporters upon proteolytic cleavage of peptide substrates. Although intact NWs are too large to pass the glomerular basement membrane, liberated reporters passively filter through the kidney. (III) The patient collects a urine sample. (IV) Application of unprocessed urine to a low-cost POC paper lateral flow assay (LFA) enables diagnosis.

**Results**

### Protease-Sensitive NPs for Urinary Monitoring of Disease

To develop synthetic biomarkers for thrombosis and cancer, we first sought to design NPs for sensing the activity of the proteases thrombin and matrix metalloproteinase 9 (MMP9). We functionalized poly(ethylene glycol)-coated iron oxide nanoworms (NWs)—a long-circulating NP formulation previously characterized by collaborators and our laboratory (19, 20)—with fluorescein-labeled substrates [PLGLRSW and PLGVRGK, respectively (8)] at a surface valency of 20–30 peptides per NW to induce intramolecular quenching (Fig. 1A). To test the efficiency of peptidolysis, we incubated thrombin-sensitive NWs with thrombin and observed a rapid increase in sample fluorescence as cleaved peptide fragments released into solution flowed freely. By contrast, no increase in fluorescence was observed in the presence of Argatroban, a direct thrombin inhibitor, or when the substrate was synthesized with protease-resistant D-stereoisomers (Fig. 2A), indicating that thrombin activity was required to activate the NWs. We observed similar increases in sample fluorescence when MMP-sensitive NWs were incubated with MMP9 and no activity when the broad-spectrum MMP inhibitor Marimastat or D-isomer substrates were used (Fig. 2B). Together, these findings showed that peptides on the surface of NWs can be efficiently cleaved by thrombin or MMP9.

We previously showed that synthetic biomarkers composed of long-circulating NWs accumulate in diseased tissue by Diffusion across fenestrated vessels such as in liver fibrosis and cancer (8), or when the sites of disease are intravascular as in thrombosis, sense protease activity while in systemic circulation (9). These studies also showed that free peptides administered i.v. are rapidly cleared by renal filtration, but their conjugation to NWs makes urinary clearance conditional upon cleavage by disease-specific proteases. To confirm that our synthetic biomarkers tailored for thrombin and MMP9 exhibit similar pharmacokinetics,
we synthesized NWs with substrates labeled with carrier peptide-linked near-infrared fluorophores to monitor peptide traffic and cleavage by in vivo fluorescence imaging. To promote renal clearance and to enable in vivo fluorescent visualization of the peptide-fluorophore reporter released by substrate proteolysis, we conjugated the near-infrared fluorophore VT750 (N-terminal) to the peptide glutamate-fibrinopeptide B (GluFib) (sequence eGvDnneeGffsaa), which we synthesized with d-amino acids (lower-case) to confer stability against protease activity (8, 9, 21).

We chose a murine model of thrombosis in which the onset of clotting is controlled by the i.v. administration of collagen and epinephrine to activate platelets and thrombin, forming blood clots that embolize to the lungs (22). Consistent with our previous findings, coadministration of NWs to mice challenged with collagen and epinephrine resulted in a pronounced increase in their urinary and lung fluorescence relative to healthy controls (Fig. 2 C and D), indicating in vivo cleavage and renal clearance of peptides. To apply to CRC, we infused MMP9-sensitive NWs into nude mice bearing s.c. human colorectal tumors (LS174T), formed by a cell line that secretes MMP9 (23), and observed similar increases in fluorescence localized to the bladder (Fig. 2E). Immunofluorescent staining of tumor sections confirmed NW (green) extravasation from the vasculature (red) into the tumor interstitium (Fig. 2F and Fig. S1). Collectively, these results verified the ability of our synthetic biomarkers to probe disease sites and release cleaved peptide fragments into the host urine.

Detecting Ligand-Encoded Reporters by Sandwich Complexes. We next sought to design a panel of ligand-encoded reporters that can be detected by protein-based sandwich complexes (Fig. 3A). The formation of a sandwich complex requires a target antigen to express two distinct epitopes that bind separately to a capture and detection agent; thus to construct the synthetic heterobifunctional reporter R1, we conjugated the ligands fluorescein (FAM; capture) and biotin (detection) to the opposing termini of the same d-stereoisomer GluFib as previously (Fig. 3A and Fig. S2F). Critically, GluFib functions as a molecular spacer, allowing FAM and biotin to bind freely to their cognate proteins α-FAM antibody (α-R1) and streptavidin, respectively, and, as before, promotes clearance of the reporter as GluFib is biologically inert and efficiently filtered by the kidneys (8, 9, 21). We first determined whether urine samples spiked with R1 could be detected by sandwich ELISA, a standard assay used in clinical laboratories. Serial dilutions of R1 were applied to a 96-well plate coated with α-R1 antibodies to immobilize R1 before NeutrAvidin-horseradish peroxidase (NA-HRP) was added to catalyze the development of the chromogenic substrate 3,3′, 5,5′-tetramethylbenzidine (TMB), revealing a linear dose dependence from ~6 pM down to the limit of detection (LOD) of ~0.1 pM (Fig. 3B and Fig. S2E). This LOD compared favorably with the sensitivity at which naturally occurring biomarkers such as prostate-specific antigen (24) can be detected by ELISA, establishing our ability to design synthetic sandwich assays by harnessing ligand–protein interactions.

To generalize our approach and construct a multiplexed library of reporters, we synthesized additional heterobifunctional derivatives of GluFib by pairing the capture ligands dimethylphenyl (DNP), tetramethylrhodamine (TMR), and Alexa Fluor 488 (AF488) with biotin to create reporters R2–R4, respectively (Fig. 3A and Fig. S2F). Similar to fluorescein, these ligands were selected because they are stable, well tolerated by living organisms, and do not elicit immune responses unless coupled to a potent immunogen (25). We developed independent sandwich ELISAs by using the antibodies α-DNP (α-R2), α-TMR (α-R3), or α-AF488 (α-R4) to capture R2, R3, or R4, respectively, and identified the LOD and working linear ranges for each, which were also within the typical values expected for sandwich ELISAs (Fig. S2A–E). Assaying for specificity revealed an increase in sample intensity in wells that contained matched antibody–ligand pairs (Fig. 3C), whereas cross-reactivity in nonmatched wells was below the LOD of the cognate detection signal (Fig. 3D). These results showed that ligand-encoded reporters can be sensitively and specifically detected in urine by sandwich ELISA.

Paper Assay Development and Detection of Protease Activity. First developed more than two decades ago to detect human chorionic gonadotropin as a home pregnancy test, paper-based LFAs have since been expanded for use in diverse settings to detect pathogens, drugs, hormones, and metabolites (17). LFAs detect antigens by a sandwich complex in which capture antibodies are immobilized onto a highly porous test strip, such as a nitrocellulose membrane, which serves to wick fluids and transport analytes from the sample pad to the capture regions (Fig. 4A). The immobilized analytes are then visualized by a detection agent coupled to NPs (typically gold or latex nanospheres) that create a colored line detectable by eye without enzymatic amplification.

Here, we sought to determine whether ligand-encoded reporters could be detected on paper. Using a low-volume robotic liquid handler, we deposited α-R1 and α-streptavidin antibodies to create test and control lines, respectively, on nitrocellulose paper strips. Unprocessed mouse urine samples spiked with R1 were then applied to the sample pads followed by a solution containing gold NP-conjugated streptavidin. Colored lines appeared where the test antibodies were printed, indicating R1 capture from urine and detection as a sandwich complex (Fig. 4B). Quantitative scans of LFAs used to analyze serial dilutions of R1 revealed a LOD of ~1 nM and a working linear range of ~1–7 nM (Fig. 4B and Fig. S5E). Similar performance metrics were observed for separate LFAs customized for the remaining reporters (Fig. S3A–E).

To enable multiplex reporter detection, we printed capture antibodies into four parallel test lines relative to a control line and analyzed urine samples that contained one of the four reporters. Similar to the ELISA results, only the test lines printed with the cognate capture antibody developed a positive signal (Fig. 4C), highlighting the LFA’s specificity and the

![Figure 3](image-url)
capacity to detect distinct reporters with single spatially encoded paper strips.

To detect protease activity by LFAs, thrombin-sensitive substrates were conjugated in tandem with R3 onto NWs. Following in vitro substrate cleavage by thrombin, we collected the peptide fragments by size-exclusion filtration. Cleaved R3 was readily detected from the filtrate by LFA, developing into significantly darker test lines compared with control samples not exposed to thrombin (Fig. 4D, \( P = 0.0022 \)). Similar results were obtained when filtrate collected after incubation of R2-encoded MMP-sensitive NWs with MMP9 was analyzed by LFA (Fig. 4E, \( P = 0.0022 \)). Together, these results demonstrated that the activity of distinct proteases can be detected by paper-based LFAs.

**Disease Detection on Paper with Synthetic Urinary Biomarkers.** Urine concentration is dependent on many host and environmental factors (e.g., diet, activity level, circadian rhythm, medical history); therefore, we sought to develop a normalization strategy for our test. We hypothesized that co-administered free reporters would pass into the urine independent of disease state and could be used to normalize the level of reporters released by protease activity. To investigate this approach, we infused a mixture of free R4 and thrombin-sensitive NWs (labeled with R3) into healthy or thrombotic cohorts of mice and collected all urine for 30 min postinjection. As anticipated, urinary concentrations of R4 were statistically equivalent between the two groups by ELISA, indicating unbiased clearance of the free reporter (Fig. 5A, Right, \( P = 0.25 \)). By contrast, urinary levels of R3, the reporter of thrombin activity, significantly increased in mice harboring thrombi when quantified independently (Fig. 5A, Left, \( P < 10^{-4} \)) or when normalized against R4 (Fig. 5B, \( P < 10^{-4} \)). Using a paper strip printed with multiple capture antibodies, we analyzed the urinary levels of R3 and R4 simultaneously (Fig. S4 and D) and similarly observed a statistically significant increase in the ratio of R3/R4 in diseased urine samples compared with healthy controls (Fig. 5C, \( P = 0.0015 \)). To determine the diagnostic accuracy of the assay, we analyzed the rate of true positives (sensitivity) and false positives (specificity) by receiver-operating characteristic (ROC) curves and found that the multiplexed paper test discriminated urine from thrombotic versus control mice accurately, with an area under the curve (a.u.c.) of 0.92 (Fig. 5D, \( P = 0.0015 \)).

To establish the ability to detect solid cancers, we adopted the normalization strategy developed for thrombosis by infusing a solution containing free R4 and R2-encoded MMP-sensitive NWs into nude mice bearing s.c. LS174T colorectal tumors and collecting all urine up to 1 h postinjection. As before, diseased mice cleared R4 with an efficiency statistically equivalent to healthy animals (Fig. 5E, Right, \( P = 0.92 \)), whereas the urinary concentrations of R2, the reporter of in vivo MMP activity, or its normalized intensity (R2/R4) were both significantly elevated in tumor-bearing mouse urine by ELISA (Fig. 5E, Left, \( P = 0.0039 \); Fig. 5F, \( P = 0.0098 \)). Analysis of the same urine samples by LFA demonstrated a significant increase in the ratio of R2/R4 in urine collected from tumor-bearing but not from control mice (Fig. 5G, \( P = 0.002 \)). By ROC analysis, this urine test was highly accurate and discriminated CRC with an a.u.c. of 0.90 (Fig. 5H, \( P = 0.0025 \)). Collectively, these results showed that LFAs can both detect synthetic biomarkers directly from the urine and discriminate NCDs with significant predictive power.

**Discussion**

In resource-limited environments, POC tests should be simple to operate, built from inexpensive components, and able to detect disease directly from biological fluids. Here, we outlined a strategy whereby NCDs are detected by a single infusion of synthetic biomarkers that release reporters into the urine in the presence of disease. Collected urine samples are then applied to custom LFAs that quantify reporter levels directly on paper without additional sample preparation or expensive instrumentation.

Building on our previous work on mass-encoded NPs, we developed LFAs that sense protease activity by releasing rationally designed ligand-encoded reporters after substrate cleavage. We showed that these heterobifunctional reporters mediate the formation of sandwich complexes detectable by standard ELISA and LFA to allow POC testing as an alternative to expensive diagnostics platforms like CT scanners or mass spectrometers, which can cost over 100-fold more than a standard microplate reader (26). Because our ligand-encoded reporters are engineered to
Fig. 5. Paper-based disease detection using synthetic urinary biomarkers. (A) Urine was collected from mice (n = 10) coinjected with R3-encoded thrombin-sensitive NWs, free R4, and either PBS or collagen/epinephrine (to induce thrombosis). By ELISA, urinary clearance of free reporter R4 was not different between control and induced animals (Right, P = 0.25), but liberated R3 was significantly increased in animals that underwent thrombosis (Left, P < 0.0001). (B) Normalization of proteolytically liberated reporter to free reporter (R3/R4) was significantly increased in diseased animals (P = 0.0001). (C) LFAs also detected significantly increased R3/R4 in urine from diseased mice from the same cohort (P < 0.0001). (D) Receiver-operating characteristic (ROC) classification by LFA detection of R3/R4 discriminated healthy from diseased mice with an a.u.c. of 0.92 (P = 0.0015) from random classifier. (E) Control or tumor-bearing mice (n = 10) were administered free R4 and R2-encoded MMP-sensitive NWs. By ELISA, R4 clearance was not affected by disease state (Right, P = 0.92) and R2 was significantly higher in CRC-positive mice (Left, P = 0.0098). (F) LFA analysis of the same urine demonstrated increased R2/R4 in diseased mice (P = 0.0020). (G) LFA quantification of R2/R4 discriminated urine from CRC-positive mice with an a.u.c. of 0.90 (P = 0.0025 from random classifier). Box plots show extremes, quartiles, and median.
by plate reader at 37 °C. Inhibitors Argatroban or Marimastat were incubated with the protease–NW mixture at 100 μM. To quantify reporter release by LFA, reporter-functionalized NWs were incubated with cognate proteases, passed through a 30-kDa M, cutoff filter, quantified by LFA, and analyzed by Mann–Whitney test.

In Vivo Imaging. All animal studies were approved by Massachusetts Institute of Technology’s committee on animal care (protocol 0411-036-14). Thrombin- or MMP-sensitive NWs were functionalized with infrared fluorescent reporter protein VIT750. Bladder and/or lung localization of proteolytically released fluorescent reporter was imaged in control and diseased mice. Thrombin was induced by injection of collagen and epinephrine with synthetic biomarkers in female Swiss Webster mice; colorectal flank tumors were induced by s.c. injection of human cell line LS174T in female NCr nude mice.

ELISA Characterization. Ninety-six-well plates were coated with capture antibodies LfA3 blocked with 1% (v/v) Tween bovine serum albumin (BSA) in 1x PBS. Reporter standards were applied and detected by addition of NeutrAvidin-horseradish peroxidase. Oxidation of chromogenic substrate TMB for 1–5 min allowed quantification of reporter concentration. All incubations were 1 hour and plates were washed with 1x PBS with 0.5% (v/v) Tween 20 between steps. Urine interference was assayed by spiking R1 in 1:100 control mouse urine. Assay specificity was measured by quantifying capture antibody or cognate antibody to all reporters and normalizing signal to a cognate reporter ladder.

Paper LFA Characterization. Capture (same as for ELISA) or control (α-strep-tavidin) antibodies were printed in 2-mm–spaced lines with 50-NL droplets at 0.5-mm pitch onto cellulose ester membrane. Membranes were laminated to a plastic backing with glass fiber conjugate and absorbent pads. The resultant construct was cut into 4-mm strips and stored at 4 °C. Reporters diluted 1:1 in urine were applied to the conjugate pad and flushed with wash buffer [1x PBS with 1% (v/v) Tween 80]. Reporters were detected using 40-nm streptavidin-gold nanoparticles. Dried strips were scanned and processed by a custom script that integrated and quantified band intensity.

Collection and Analysis of Urinary Peptides. Urine was collected from mice i.v. infused with synthetic biomarker mixtures (free R4 plus either R3-functionalized thrombin-sensitive NWs to detect thrombosis or R2-functionalized MMP-sensitive NWs to detect CRC) for 30 or 60 min postinjection (to detect thrombosis or CRC, respectively). Urine collection times were optimized from previous studies using these disease models (8, 9) and are dependent on site of disease and rate of enzymatic substrate cleavage. Reporter concentration in unprocessed urine was assayed by above protocols from urine diluted 1:10 to 10 for ELISA or 1:4–5 for LFA. Data were analyzed using ROC curves (both) and Wilcoxon signed rank test (CRC) or Mann–Whitney test (thrombosis).

ACKNOWLEDGMENTS. We thank Prof. B. Engelward for use of the robotic liquid handler, Dr. H. Fleming for helpful guidance, and J. Gómez-Márquez for LFA development insights. A.D.W. thanks the National Science Foundation Graduate Research Fellowship Program for support. D.K.W. acknowledges support by the Mazumdar–Shaw International Oncology Fellowship. G.A.K. acknowledges support from National Research Service Award F32CA152946-02 and holds a Career Award at the Scientific Interface from the Burroughs Wellcome Fund. K.Y.L. acknowledges support from Center of Cancer Nanotechnology Excellence Grant S 054 CA151884-03. We thank the Koch Institute Swanson Biotechnology Center for technical support, specifically Richard Cook and the Biopolymers and Proteomics Core. This work was supported in part by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. S.N.B. is a Howard Hughes Medical Institute investigator.